Theravance Biopharma Inc
(STU:0TB)
€
7.5
-0.1 (-1.32%)
Market Cap: 369.83 Mil
Enterprise Value: 324.39 Mil
PE Ratio: 0
PB Ratio: 2.08
GF Score: 59/100 Theravance Biopharma Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022 / 03:10PM GMT
Release Date Price:
€9.2
(+1.66%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
All right. Thanks, everyone, for joining. Appreciate it. Let's go ahead and get started. My name is Vikram Purohit. I'm one of the biotech analysts with Morgan Stanley Research. Happy to have with me on the stage Theravance Biopharma.
Let me read a quick disclosure statement before we get started. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
With that, happy to have with me Rick Winningham, CEO; Andrew Hindman, CFO; and Rhonda Farnum. Thank you for joining us. Appreciate it.
Rick E. Winningham
Theravance Biopharma, Inc. - Chairman & CEO
Happy to be here.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Rick, maybe
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot